Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Acne Vulgaris - Overview
Acne Vulgaris - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Acne Vulgaris - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Acne Vulgaris - Companies Involved in Therapeutics Development
Acne Vulgaris - Drug Profiles
Acne Vulgaris - Dormant Projects
Acne Vulgaris - Discontinued Products
Acne Vulgaris - Product Development Milestones
Featured News & Press Releases
Mar 25, 2022: Sun Pharma presents phase 3 data for WINLEVI (clascoterone) cream 1% for the topical treatment of acne vulgaris at the AAD Annual Meeting
Feb 03, 2022: Kintor Pharmaceutical: Voluntary announcement first subject dosing in phase I clinical trial of GT20029 (ar-protac) in the United States
Jan 24, 2022: Kintor Pharmaceutical : Voluntary announcement dosing of first patient for acne vulgaris phase II clinical trial of KX-826 in Chi
Jan 24, 2022: Kintor Pharma Announced successful dosing of the first patient for acne vulgaris phase II clinical trial of KX-826
Jan 14, 2022: Ascletis doses first participant in Phase II acne oral therapy trial
Dec 17, 2021: Lipidor expands clinical program, announces investment in new drug development project against acne vulgaris
Nov 01, 2021: Sun Pharma announces availability of WINLEVI (clascoterone) cream 1% in the U.S. for topical treatment of acne vulgaris
Oct 05, 2021: VYNE Therapeutics Announces its Chi partner’s enrollment of first patient in phase 3 study of AMZEEQ in patients with moderate to severe acne
Sep 13, 2021: Voluntary announcement Adapalene Clindamycin Hydrochloride combition gel passing the on site inspection for drug registration in Chi becoming the third GMP inspection that the company has passed this year
Aug 08, 2021: Chi NMPA approves Phase II clinical trial of ASC40 for the treatment of patients with Acne
Jul 28, 2021: Kintor Pharmaceutical announces dosing of first batch of subjects in phase I clinical trial of GT20029 in Chi
Jul 19, 2021: VYNE announces initiation of investigator initiated trial evaluating AMZEEQ (minocycline) with oral isotretinoin in patients with moderate to severe acne
Jul 13, 2021: Hoth Therapeutics announces positive confirmatory results from in vivo model of HT-003 assets as potential treatment against acne
Jul 13, 2021: Kintor Pharmaceutical receives IND clearance by the U.S. FDA for GT20029 to treat androgenetic alopecia and acne
Jun 01, 2021: Almirall receives FDA approval to produce Seysara (sarecycline) at the Sant Andreu de la Barca (Barcelo) plant
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development for Acne Vulgaris, 2022
Number of Products under Development by Companies, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022

List of Tables

List of Tables
Number of Products under Development for Acne Vulgaris, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Target, 2022 (Contd..1)
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Acne Vulgaris - Pipeline by Akaal Pharma Pty Ltd, 2022
Acne Vulgaris - Pipeline by AMD Therapeutics LLC, 2022
Acne Vulgaris - Pipeline by Amgen Inc, 2022
Acne Vulgaris - Pipeline by Amytrx Therapeutics Inc, 2022
Acne Vulgaris - Pipeline by Annji Pharmaceutical Co Ltd, 2022
Acne Vulgaris - Pipeline by AOBiome LLC, 2022
Acne Vulgaris - Pipeline by Arcutis Biotherapeutics Inc, 2022
Acne Vulgaris - Pipeline by Atacama Therapeutics Inc, 2022
Acne Vulgaris - Pipeline by Attillaps Holdings Inc, 2022
Acne Vulgaris - Pipeline by Avecho Biotechnology Ltd, 2022
Acne Vulgaris - Pipeline by Avicanna Inc, 2022
Acne Vulgaris - Pipeline by Bausch Health Companies Inc, 2022
Acne Vulgaris - Pipeline by Biofrontera AG, 2022
Acne Vulgaris - Pipeline by Biozeus Pharmaceutical SA, 2022
Acne Vulgaris - Pipeline by Blueberry Therapeutics Ltd, 2022
Acne Vulgaris - Pipeline by Boston Pharmaceuticals Inc, 2022
Acne Vulgaris - Pipeline by Botanix Pharmaceuticals Ltd, 2022
Acne Vulgaris - Pipeline by Boulos and Cooper Pharmaceuticals Pty Ltd, 2022
Acne Vulgaris - Pipeline by Claritas Pharmaceuticals Inc, 2022
Acne Vulgaris - Pipeline by Clinuvel Pharmaceuticals Ltd, 2022
Acne Vulgaris - Pipeline by Cosmo Pharmaceuticals NV, 2022
Acne Vulgaris - Pipeline by Cutanea Life Sciences Inc, 2022
Acne Vulgaris - Pipeline by Dermata Therapeutics Inc, 2022
Acne Vulgaris - Pipeline by Dermavant Sciences Inc, 2022
Acne Vulgaris - Pipeline by Devonian Health Group Inc, 2022
Acne Vulgaris - Pipeline by Eligo Bioscience SA, 2022
Acne Vulgaris - Pipeline by Galephar Pharmaceutical Research Inc, 2022
Acne Vulgaris - Pipeline by Hoth Therapeutics Inc, 2022
Acne Vulgaris - Pipeline by Innovation Pharmaceuticals Inc, 2022
Acne Vulgaris - Pipeline by Journey Medical Corp, 2022
Acne Vulgaris - Pipeline by Kintor Pharmaceutical Ltd, 2022
Acne Vulgaris - Pipeline by Lee’s Pharmaceutical Holdings Ltd, 2022
Acne Vulgaris - Pipeline by Lipidio Pharmaceuticals Inc, 2022
Acne Vulgaris - Pipeline by Lipidor AB, 2022
Acne Vulgaris - Pipeline by Madam Therapeutics BV, 2022
Acne Vulgaris - Pipeline by Maruho Co Ltd, 2022
Acne Vulgaris - Pipeline by Matrisys Bioscience Inc, 2022
Acne Vulgaris - Pipeline by Mayne Pharma Group Ltd, 2022
Acne Vulgaris - Pipeline by Melinta Therapeutics Inc, 2022
Acne Vulgaris - Pipeline by Novabiotics Ltd, 2022
Acne Vulgaris - Pipeline by Novan Inc, 2022
Acne Vulgaris - Pipeline by Novartis AG, 2022
Acne Vulgaris - Pipeline by Ortho Dermatologics Inc, 2022
Acne Vulgaris - Pipeline by Paratek Pharmaceuticals Inc, 2022
Acne Vulgaris - Pipeline by Phagelux Inc, 2022
Acne Vulgaris - Pipeline by PHI Therapeutics Inc, 2022
Acne Vulgaris - Pipeline by Promius Pharma LLC, 2022
Acne Vulgaris - Pipeline by Provectus Biopharmaceuticals Inc, 2022
Acne Vulgaris - Pipeline by Revive Therapeutics Ltd, 2022
Acne Vulgaris - Pipeline by Riptide Bioscience Inc, 2022
Acne Vulgaris - Pipeline by Sagimet Biosciences Inc, 2022
Acne Vulgaris - Pipeline by Sanofi, 2022
Acne Vulgaris - Pipeline by SaNOtize Research and Development Corp, 2022
Acne Vulgaris - Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd, 2022
Acne Vulgaris - Pipeline by Timber Pharmaceuticals Inc, 2022
Acne Vulgaris - Pipeline by Verge Therapeutics Inc, 2022
Acne Vulgaris - Pipeline by VYNE Therapeutics Inc, 2022
Acne Vulgaris - Pipeline by Vyome Therapeutics Inc, 2022
Acne Vulgaris - Dormant Projects, 2022
Acne Vulgaris - Discontinued Products, 2022